Sterilisation device to undergo US Phase II trials:
This article was originally published in Clinica
Executive Summary
Conceptus is to begin US Phase II clinical trials of its S/TOP device for permanent contraception. The effectiveness of the selective tubal occlusion procedure device, which is deployed permanently into each fallopian tube, will be assessed in an initial study of 15 patients. The company, based in San Carlos, California, began its first Phase II clinical trial of the device at a single site in Australia last year.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.